Brand Name | Status | Last Update |
---|---|---|
ninlaro | New Drug Application | 2024-09-09 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple myeloma | — | D009101 | C90.0 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 5 | 19 | 5 | 3 | 6 | 34 |
Plasma cell neoplasms | D054219 | — | — | 5 | 18 | 5 | 3 | 5 | 32 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Frailty | D000073496 | — | R53.1 | — | — | 1 | — | — | 1 |
Hematopoietic stem cell transplantation | D018380 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 3 | 5 | — | — | — | 5 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 2 | — | — | — | 2 |
Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 1 | — | — | — | 2 |
Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 1 | — | — | — | 1 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 1 | — | — | — | 1 |
Lymphoid leukemia | D007945 | — | C91 | 1 | 1 | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 1 |
Smoldering multiple myeloma | D000075122 | — | — | — | 1 | — | — | — | 1 |
T-cell lymphoma | D016399 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 1 | — | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Liposarcoma | D008080 | — | — | 1 | — | — | — | — | 1 |
Alveolar soft part sarcoma | D018234 | — | — | 1 | — | — | — | — | 1 |
Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | — | 1 |
Neurofibrosarcoma | D018319 | — | — | 1 | — | — | — | — | 1 |
Nerve sheath neoplasms | D018317 | EFO_0000760 | — | 1 | — | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Lupus nephritis | D008181 | EFO_0005761 | — | 1 | — | — | — | — | 1 |
Nephritis | D009393 | — | N05 | 1 | — | — | — | — | 1 |
Drug common name | Ixazomib |
INN | ixazomib |
Description | Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. It has a role as an apoptosis inducer, an orphan drug, a proteasome inhibitor, a drug metabolite and an antineoplastic agent. It is a member of benzamides, a dichlorobenzene, a glycine derivative and a member of boronic acids. |
Classification | Small molecule |
Drug class | proteozome inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O |
PDB | — |
CAS-ID | 1072833-77-2 |
RxCUI | — |
ChEMBL ID | CHEMBL2141296 |
ChEBI ID | — |
PubChem CID | 25183872 |
DrugBank | DB09570 |
UNII ID | 71050168A2 (ChemIDplus, GSRS) |